Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 4/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1328092 | 0.90 | KMT2A (0.50) | TSHRKMT2APKMMAPTMAPK1 | |
| SCHEMBL1328303 | 0.89 | TSHR (0.49) | TSHRKMT2APKMMAPTMAPK1 | |
| SCHEMBL1329280 | 0.84 | C5AR1 (0.46) | TSHRMAPTC5AR1 | |
| SCHEMBL1328066 | 0.84 | C5AR1 (0.42) | TSHRMAPTMAPK1ALDH1A1C5AR1 | |
| SCHEMBL1329868 | 0.83 | RAB9A (0.47) | TSHRKMT2APKMMAPTMAPK1 | |
| SCHEMBL1327671 | 0.83 | C5AR1 (0.46) | RAB9AALDH1A1MAOBC5AR1 | |
| SCHEMBL1328338 | 0.83 | C5AR1 (0.41) | TSHRKMT2AMAPTMAPK1ALDH1A1 | |
| SCHEMBL1330008 | 0.82 | C5AR1 (0.44) | C5AR1CD274 | |
| SCHEMBL1327460 | 0.82 | C5AR1 (0.43) | C5AR1 | |
| SCHEMBL1329327 | 0.82 | C5AR1 (0.45) | MAPTALDH1A1C5AR1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | TSHR 231/4885KMT2A 3960/4885PKM 3457/4885 |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | TSHR 231/4885KMT2A 3960/4885PKM 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.